On the public citation graph
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
0 signed · 358 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cncr.29098openalex-snapshot
Small cell lung cancer: Where do we go from here?
inferredcites →https://doi.org/10.1056/nejm199901283400403openalex-snapshot
Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide
inferredcites →https://doi.org/10.1093/annonc/mdq036openalex-snapshot
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
inferredcites →https://doi.org/10.1200/jco.2005.04.4859openalex-snapshot
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database
inferredcites →https://doi.org/10.1200/jco.2005.04.8595openalex-snapshot
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2008.20.1061openalex-snapshot
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.7503openalex-snapshot
Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.
inferredcites →https://doi.org/10.1200/jco.2014.56.7081openalex-snapshot
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
inferredcites →https://doi.org/10.1378/chest.12-2363openalex-snapshot
Treatment of Small Cell Lung Cancer
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4634929openalex-extracted
Lipid Metabolism-Related Genes: Novel Predictors for the Transition from Bronchial Asthma to Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.15748openalex-snapshot
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2016.1779openalex-snapshot
Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology
inferred← citeshttps://doi.org/10.1002/14651858.cd013025openalex-snapshot
Third-line systemic chemotherapy for small cell lung cancer
inferred← citeshttps://doi.org/10.1002/14651858.cd014559openalex-snapshot
Prophylactic cranial irradiation for extensive-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cam4.1616openalex-snapshot
Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cam4.5082openalex-snapshot
Prophylactic cranial irradiation for limited‐stage small‐cell lung cancer in the magnetic resonance imaging era
inferred← citeshttps://doi.org/10.1002/cam4.72126openalex-snapshot
Chemotherapy and Radiotherapy Regimens for Limited‐Stage Small Cell Lung Cancer Treated With Accelerated Hyperfractionated Radiotherapy Combined With Chemotherapy: A Real‐World Study
inferred← citeshttps://doi.org/10.1002/cam4.7215openalex-snapshot
Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial
inferred← citeshttps://doi.org/10.1002/cnr2.1243openalex-snapshot
A noteworthy treatment of metastatic small‐cell lung cancer with afatinib, followed by subsequent development of rare metastatic lesions in the ascending and sigmoid colon
inferred← citeshttps://doi.org/10.1002/jcph.2346openalex-snapshot
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
inferred← citeshttps://doi.org/10.1002/onco.13772openalex-snapshot
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
inferred← citeshttps://doi.org/10.1002/pds.5179openalex-snapshot
Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
inferred← citeshttps://doi.org/10.1002/tox.24152openalex-snapshot
Tumor markers for lipid metabolism‐related genes: Based on small cell lung cancer and bronchial asthma dual analysis
inferred← citeshttps://doi.org/10.1007/16833_2024_283openalex-snapshot
Natural Killer Cells in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-42958-4_1openalex-snapshot
Epidemiology and Socioeconomic Impact of CNS Metastases
inferred← citeshttps://doi.org/10.1007/978-3-030-93084-4_41openalex-snapshot
Metastatic Disease of the Lung
inferred← citeshttps://doi.org/10.1007/978-3-319-30046-7_8openalex-snapshot
Neuroendocrine and Small Cell Carcinoma of the Urinary Tract
inferred← citeshttps://doi.org/10.1007/978-3-319-44870-1_63-1openalex-snapshot
Respiratory Organ Aging and Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-57415-8_63openalex-snapshot
Respiratory Organ Aging and Cancer
inferred← citeshttps://doi.org/10.1007/978-981-10-6469-2_1openalex-snapshot
Molecular Diagnosis and Targeting for Lung Cancer
inferred← citeshttps://doi.org/10.1007/s00066-016-1069-6openalex-snapshot
Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00066-019-01457-2openalex-snapshot
Re-irradiation in locally recurrent lung cancer patients
inferred← citeshttps://doi.org/10.1007/s00262-021-02926-3openalex-snapshot
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
inferred← citeshttps://doi.org/10.1007/s00408-022-00549-8openalex-snapshot
Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
inferred← citeshttps://doi.org/10.1007/s00520-026-10936-zopenalex-snapshot
Impact of weight loss on adverse events during chemoradiotherapy in patients with small cell lung cancer: a retrospective study
inferred← citeshttps://doi.org/10.1007/s00595-018-1659-2openalex-snapshot
A liquid biopsy in primary lung cancer
inferred← citeshttps://doi.org/10.1007/s00761-016-0073-xopenalex-snapshot
Kleinzelliges Lungenkarzinom
inferred← citeshttps://doi.org/10.1007/s00761-021-00959-yopenalex-snapshot
Behandlung des kleinzelligen Lungenkarzinoms
inferred← citeshttps://doi.org/10.1007/s00761-024-01567-2openalex-snapshot
Chirurgie beim kleinzelligen Lungenkarzinom
inferred← citeshttps://doi.org/10.1007/s10330-018-0324-4openalex-snapshot
Progress in the diagnosis and treatment of extensive-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s10637-022-01279-7openalex-snapshot
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
inferred← citeshttps://doi.org/10.1007/s10637-023-01411-1openalex-snapshot
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
inferred← citeshttps://doi.org/10.1007/s11096-024-01802-1openalex-snapshot
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
inferred← citeshttps://doi.org/10.1007/s11523-021-00843-0openalex-snapshot
Durvalumab: A Review in Extensive-Stage SCLC
inferred← citeshttps://doi.org/10.1007/s11523-023-00995-1openalex-snapshot
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis
inferred← citeshttps://doi.org/10.1007/s11523-026-01207-2openalex-snapshot
Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s11654-024-00610-3openalex-snapshot
Chirurgie beim kleinzelligen Lungenkarzinom
inferred← citeshttps://doi.org/10.1007/s11655-022-3682-9openalex-snapshot
Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s12032-017-0966-6openalex-snapshot
Progress and challenges in the treatment of small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12094-017-1617-2openalex-snapshot
Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12094-018-02011-9openalex-snapshot
The role of immunotherapy in small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12094-024-03690-3openalex-snapshot
Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy
inferred← citeshttps://doi.org/10.1007/s12094-025-03918-wopenalex-snapshot
Treatment patterns and survival outcomes in patients with small-cell lung cancer following failure of first-line platinum-based chemotherapy
inferred← citeshttps://doi.org/10.1007/s12672-025-02998-yopenalex-snapshot
Circulating soluble fibroblast activation protein (FAP) in patients with intra-thoracic cancer undergoing chest radiation
inferred← citeshttps://doi.org/10.1007/s13139-017-0490-9openalex-snapshot
Prognostic Value of Pre- and Post-Treatment FDG PET/CT Parameters in Small Cell Lung Cancer Patients
inferred← citeshttps://doi.org/10.1007/s40259-023-00586-6openalex-snapshot
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing
inferred← citeshttps://doi.org/10.1007/s40265-020-01398-6openalex-snapshot
Atezolizumab: A Review in Extensive-Stage SCLC
inferred← citeshttps://doi.org/10.1016/b978-0-323-44284-8.00014-4openalex-snapshot
Neuroendocrine Neoplasms of the Lung
inferred← citeshttps://doi.org/10.1016/b978-0-323-48565-4.00007-2openalex-snapshot
A Practical Approach to Management of Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-79547-0.00023-0openalex-snapshot
Neuroendocrine neoplasms of the lung
inferred← citeshttps://doi.org/10.1016/b978-0-323-89843-0.00013-1openalex-snapshot
Exercise in cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-91338-6.00040-9openalex-snapshot
Vitamin D in the management of lung cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-93548-7.00026-xopenalex-snapshot
Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1016/b978-0-443-31656-2.00005-0openalex-snapshot
Lung cancer: Current status of preclinical research
inferred← citeshttps://doi.org/10.1016/j.acra.2018.10.013openalex-snapshot
Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography
inferred← citeshttps://doi.org/10.1016/j.acra.2023.10.020openalex-snapshot
Delta Radiomics Model for the Prediction of Overall Survival and Local Recurrence in Small Cell Lung Cancer Patients After Chemotherapy
inferred← citeshttps://doi.org/10.1016/j.adro.2017.08.001openalex-snapshot
Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.adro.2023.101413openalex-snapshot
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
inferred← citeshttps://doi.org/10.1016/j.athoracsur.2016.11.039openalex-snapshot
Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.athoracsur.2017.07.009openalex-snapshot
Surgical Treatment for Early Small Cell Lung Cancer: Variability in Practice and Impact on Survival
inferred← citeshttps://doi.org/10.1016/j.athoracsur.2024.01.012openalex-snapshot
Disparities and Underutilization of Surgery for Early Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2018.08.007openalex-snapshot
Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2022.215852openalex-snapshot
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ccell.2021.09.008openalex-snapshot
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.clinthera.2020.01.011openalex-snapshot
The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.cllc.2017.03.003openalex-snapshot
Disparities in the Management of Patients With Stage I Small Cell Lung Carcinoma (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis
inferred← citeshttps://doi.org/10.1016/j.cllc.2017.08.004openalex-snapshot
Prophylactic Cranial Irradiation for Resectable Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2019.06.014openalex-snapshot
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.02.013openalex-snapshot
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.04.006openalex-snapshot
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.06.004openalex-snapshot
Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival
inferred← citeshttps://doi.org/10.1016/j.cllc.2021.06.007openalex-snapshot
VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis
inferred← citeshttps://doi.org/10.1016/j.clon.2024.06.056openalex-snapshot
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.03.012openalex-snapshot
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.08.010openalex-snapshot
Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate
inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100405openalex-snapshot
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100493openalex-snapshot
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide
inferred← citeshttps://doi.org/10.1016/j.ctarc.2025.100874openalex-snapshot
PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.06.023openalex-snapshot
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
inferred← citeshttps://doi.org/10.1016/j.ejca.2025.116059openalex-snapshot
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174298openalex-snapshot
Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejso.2016.04.063openalex-snapshot
A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells
inferred← citeshttps://doi.org/10.1016/j.esmoop.2025.105918openalex-snapshot
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
inferred← citeshttps://doi.org/10.1016/j.gendis.2026.102143openalex-snapshot
Proteomic characterization of small cell lung cancer uncovers innate-adaptive immune dynamics and immunotherapeutic vulnerabilities
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2023.06.695openalex-snapshot
Role and Modality of Combining Radiotherapy with Immunotherapy in Stage III-IV Unresectable Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2026.09.021openalex-snapshot
A Novel TCP and NTCP Modeling Framework Incorporating Inter-Fractional Deviations and Biological Effectiveness for Hyper-fractionated Radiotherapy
inferred← citeshttps://doi.org/10.1016/j.ijsu.2017.09.072openalex-snapshot
The revision of 8th edition TNM stage criteria is more accurate in prediction postoperative survival for SCLC patients
inferred← citeshttps://doi.org/10.1016/j.intimp.2019.105747openalex-snapshot
Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines
inferred← citeshttps://doi.org/10.1016/j.isci.2021.102953openalex-snapshot
ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.isci.2024.110132openalex-snapshot
Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC
inferred← citeshttps://doi.org/10.1016/j.jgo.2018.10.001openalex-snapshot
The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada
inferred← citeshttps://doi.org/10.1016/j.jtho.2017.11.004openalex-snapshot
Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
inferred← citeshttps://doi.org/10.1016/j.jtho.2018.02.024openalex-snapshot
The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.jtho.2018.09.027openalex-snapshot
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.01.008openalex-snapshot
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.01.019openalex-snapshot
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.01.028openalex-snapshot
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.03.023openalex-snapshot
18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.05.009openalex-snapshot
Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung
inferred← citeshttps://doi.org/10.1016/j.jtho.2023.01.012openalex-snapshot
Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC
inferred← citeshttps://doi.org/10.1016/j.jtho.2023.09.1446openalex-snapshot
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jtho.2026.103703openalex-snapshot
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2021.100270openalex-snapshot
Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2024.100764openalex-snapshot
Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.07.014openalex-snapshot
O 6 -Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.10.003openalex-snapshot
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.11.016openalex-snapshot
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.03.004openalex-snapshot
Targeted therapy in small cell lung cancer: A new era?
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.05.004openalex-snapshot
Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.09.004openalex-snapshot
Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2017.09.013openalex-snapshot
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.02.026openalex-snapshot
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.08.024openalex-snapshot
Immune checkpoint blockade in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.09.003openalex-snapshot
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.02.002openalex-snapshot
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2024.107819openalex-snapshot
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108678openalex-snapshot
Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT)
inferred← citeshttps://doi.org/10.1016/j.lungcan.2026.109520openalex-snapshot
Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206
inferred← citeshttps://doi.org/10.1016/j.med.2025.03.008openalex-snapshot
Protocolo de manejo multimodal del cáncer de pulmón: cirugía, radioterapia y tratamiento sistémico. Indicaciones terapéuticas y paliativas de la cirugía y la radioterapia
inferred← citeshttps://doi.org/10.1016/j.prro.2016.01.011openalex-snapshot
Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age > 65 years) using national SEER-Medicare data
inferred← citeshttps://doi.org/10.1016/j.radonc.2020.07.012openalex-snapshot
ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.rmr.2021.05.008openalex-snapshot
Chirurgie du cancer pulmonaire à petites cellules
inferred← citeshttps://doi.org/10.1016/j.thorsurg.2017.08.003openalex-snapshot
Thoracic Surgery in Early-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.urolonc.2018.02.015openalex-snapshot
Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome
inferred← citeshttps://doi.org/10.1016/j.xjon.2025.07.013openalex-snapshot
Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/s0140-6736(19)32222-6openalex-snapshot
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
inferred← citeshttps://doi.org/10.1016/s1470-2045(21)00083-8openalex-snapshot
Combination treatment options for small-cell lung cancer – Authors' reply
inferred← citeshttps://doi.org/10.1016/s1470-2045(22)00224-8openalex-snapshot
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
inferred← citeshttps://doi.org/10.1016/s1877-1203(24)00080-6openalex-snapshot
Chirurgie du cancer à petites cellules
inferred← citeshttps://doi.org/10.1016/s2213-2600(24)00189-9openalex-snapshot
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
inferred← citeshttps://doi.org/10.1038/nrc.2017.87openalex-snapshot
Small-cell lung cancer: what we know, what we need to know and the path forward
inferred← citeshttps://doi.org/10.1038/s41392-024-01974-2openalex-snapshot
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial
inferred← citeshttps://doi.org/10.1038/s41416-022-02103-yopenalex-snapshot
Molecular features and evolutionary trajectory of ASCL1+ and NEUROD1+ SCLC cells
inferred← citeshttps://doi.org/10.1038/s41540-023-00316-2openalex-snapshot
Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways
inferred← citeshttps://doi.org/10.1038/s41598-025-20649-8openalex-snapshot
Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China
inferred← citeshttps://doi.org/10.1039/d1dt02611aopenalex-snapshot
Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru( ii )- p -cymene complexes with acylthiourea ligands— in vitro and in vivo studies
inferred← citeshttps://doi.org/10.1053/j.semtcvs.2020.02.003openalex-snapshot
Endobronchial Ultrasound-Guided Radiofrequency Ablation of Lung Tumors and Mediastinal Lymph Nodes: A Preclinical Study in Animal Lung Tumor and Mediastinal Adenopathy Models
inferred← citeshttps://doi.org/10.1055/s-0043-115642openalex-snapshot
Aktuelle Indikationen zur operativen Therapie beim kleinzelligen Lungenkarzinom
inferred← citeshttps://doi.org/10.1080/14737140.2018.1453361openalex-snapshot
Current and future therapeutic approaches for the treatment of small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14737167.2021.1888717openalex-snapshot
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
inferred← citeshttps://doi.org/10.1080/14737167.2023.2281606openalex-snapshot
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
inferred← citeshttps://doi.org/10.1080/14796694.2026.2623038openalex-snapshot
Impact of immunotherapy on survival and treatment patterns of patients with extensive-stage small cell lung cancer: a study using a Japanese nationwide database
inferred← citeshttps://doi.org/10.1080/15384101.2017.1339849openalex-snapshot
Family matters: How MYC family oncogenes impact small cell lung cancer
inferred← citeshttps://doi.org/10.1080/17476348.2021.1964362openalex-snapshot
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment
inferred← citeshttps://doi.org/10.1080/17512433.2021.1911640openalex-snapshot
Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab
inferred← citeshttps://doi.org/10.1093/icvts/ivy223openalex-snapshot
Is lobectomy superior to sublobar resection for early-stage small-cell lung cancer discovered intraoperatively?
inferred← citeshttps://doi.org/10.1093/jnci/djw119openalex-snapshot
Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1093/jrr/rrz040openalex-snapshot
Role of prophylactic cranial irradiation for elderly patients with limited-disease small-cell lung cancer: inverse probability of treatment weighting using propensity score
inferred← citeshttps://doi.org/10.1093/oncolo/oyae234openalex-snapshot
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002693openalex-snapshot
Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation
inferred← citeshttps://doi.org/10.1097/coc.0000000000000867openalex-snapshot
Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/coc.0000000000001066openalex-snapshot
Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/jcma.0000000000000576openalex-snapshot
Treatment patterns and survival in patients with small cell lung cancer in Taiwan
inferred← citeshttps://doi.org/10.1097/md.0000000000006985openalex-snapshot
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma
inferred← citeshttps://doi.org/10.1097/md.0000000000008922openalex-snapshot
A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy
inferred← citeshttps://doi.org/10.1097/md.0000000000017214openalex-snapshot
Surgery for small cell lung cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000027029openalex-snapshot
Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
inferred← citeshttps://doi.org/10.1097/mjt.0000000000000686openalex-snapshot
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/rct.0000000000000847openalex-snapshot
Lesser Known Facts of Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/sla.0000000000002287openalex-snapshot
Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1101/2020.08.13.249029openalex-snapshot
Lineage transcription factors co-regulate subtype-specific genes providing a roadmap for systematic identification of small cell lung cancer vulnerabilities
inferred← citeshttps://doi.org/10.1111/1754-9485.13269openalex-snapshot
Prophylactic cranial irradiation confers favourable prognosis for patients with limited‐stage small cell lung cancer in the era of MRI: A propensity score‐matched analysis
inferred← citeshttps://doi.org/10.1111/1759-7714.12943openalex-snapshot
Choice of surgical procedure – lobectomy, segmentectomy, or wedge resection – for patients with stage T1‐2N0M0 small cell lung cancer: A population‐based study
inferred← citeshttps://doi.org/10.1111/1759-7714.14048openalex-snapshot
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer ( HOT1401 / NJLCG1401 )
inferred← citeshttps://doi.org/10.1111/1759-7714.14330openalex-snapshot
Radiation therapy induces an abscopal effect and upregulates programmed death‐ligand 1 expression in a patient with non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.14697openalex-snapshot
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide‐platinum‐atezolizumab treatment
inferred← citeshttps://doi.org/10.1111/1759-7714.15178openalex-snapshot
Advances in new targets for immunotherapy of small cell lung cancer
inferred← citeshttps://doi.org/10.1111/cas.14284openalex-snapshot
Ubiquitin C‐terminal hydrolase‐L1 has prognostic relevance and is a therapeutic target for high‐grade neuroendocrine lung cancers
inferred← citeshttps://doi.org/10.1111/cas.70188openalex-snapshot
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 ADRIATIC Trial
inferred← citeshttps://doi.org/10.1111/crj.12901openalex-snapshot
Airway stenting for patients with airway stenosis because of small cell lung cancer
inferred← citeshttps://doi.org/10.1111/crj.13715openalex-snapshot
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
inferred← citeshttps://doi.org/10.1111/ecc.13250openalex-snapshot
Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
inferred← citeshttps://doi.org/10.1136/jitc-2021-002554openalex-snapshot
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
inferred← citeshttps://doi.org/10.1155/2021/9949714openalex-snapshot
Sites of Synchronous Distant Metastases, Prognosis, and Nomogram for Small Cell Lung Cancer Patients with Bone Metastasis: A Large Cohort Retrospective Study
inferred← citeshttps://doi.org/10.1158/0008-5472.c.6513732.v1openalex-snapshot
Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
inferred← citeshttps://doi.org/10.1158/0008-5472.can-16-1467openalex-snapshot
Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity
inferred← citeshttps://doi.org/10.1158/0008-5472.can-21-2964openalex-snapshot
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530028openalex-snapshot
Data from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530028.v1openalex-snapshot
Data from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530718.v1openalex-snapshot
Data from Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-17-1401openalex-snapshot
Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-2845openalex-snapshot
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-4259openalex-snapshot
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-22-2242openalex-snapshot
Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1159/000501548openalex-snapshot
Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status
inferred← citeshttps://doi.org/10.1159/000506383openalex-snapshot
Therapie des kleinzelligen Lungenkarzinoms bei neu diagnostizierten Patienten mit schlechtem Performance-Status
inferred← citeshttps://doi.org/10.1159/000510534openalex-snapshot
Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis
inferred← citeshttps://doi.org/10.1159/000516506openalex-snapshot
Feasibility and Safety of Radiofrequency Ablation Guided by Bronchoscopic Transparenchymal Nodule Access in Canines
inferred← citeshttps://doi.org/10.1177/0218492319826724openalex-snapshot
Surgical outcomes of early-stage small-cell lung cancer: single-center experience
inferred← citeshttps://doi.org/10.1177/1010428320958603openalex-snapshot
A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test
inferred← citeshttps://doi.org/10.1177/10732748251351754openalex-snapshot
Peritumoral Radiomic Features on CT for Differential Diagnosis in Small-Cell Lung Cancer: Potential for Surgical Decision-Making
inferred← citeshttps://doi.org/10.1177/1533033820977546openalex-snapshot
RETRACTED: microRNA-195 Promotes Small Cell Lung Cancer Cell Apoptosis via Inhibiting Rap2C Protein-Dependent MAPK Signal Transduction
inferred← citeshttps://doi.org/10.1177/15330338211050775openalex-snapshot
Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
inferred← citeshttps://doi.org/10.1177/17588359221146134openalex-snapshot
The postoperative prognosis of skip-N2 metastasis is favorable in small-cell lung carcinoma patients with pathological N2 classification: a propensity-score-adjusted retrospective multicenter study
inferred← citeshttps://doi.org/10.1177/17588359231206147openalex-snapshot
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial
inferred← citeshttps://doi.org/10.1177/17588359261463145openalex-snapshot
Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework
inferred← citeshttps://doi.org/10.1177/17588359261466640openalex-snapshot
Immunotherapy and the novel therapeutic development for small-cell lung cancer
inferred← citeshttps://doi.org/10.1183/13993003.00422-2017openalex-snapshot
Treatment of limited disease small cell lung cancer: the multidisciplinary team
showing the first 200 of 348 · page through all 348
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.